Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma

NCT05737199 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Squamous Cell Carcinoma

Interventions

DRUG: MK-3475 (pembrolizumab)

Sponsor

Niigata University Medical & Dental Hospital

Collaborators

[object Object]